WebJan 15, 2024 · Purpose: Metaplastic breast cancer (MpBC) is a rare aggressive subtype that responds poorly to cytotoxics. Median survival is approximately 8 months for metastatic disease. We report results for advanced MpBC treated with ipilimumab + nivolumab, a cohort of S1609 for rare cancers (DART: NCT02834013). Patients and methods: … WebApr 14, 2024 · Abstract. Background: Dual checkpoint inhibition with anti-PD-1 and anti-CTLA4 checkpoint inhibitors have proven to be efficacious in numerous malignancies. …

A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 ... - PubMed

WebNov 1, 2024 · (PDF) 795 A multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA … WebApr 21, 2024 · Here they sought to validate their findings in a dedicated prospective cohort of high-grade neuroendocrine neoplasms within S1609. Methods A prospective, open … holiday inn hamilton blvd

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab …

WebS1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in rare tumors MD Anderson Study Status Not Accepting Treatment Agent Ipilimumab, Nivolumab Description This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. WebMulticenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 … WebMar 28, 2024 · Here they sought to validate their findings in a dedicated prospective cohort of high-grade neuroendocrine neoplasms within S1609. Methods: A prospective, open-label, multicenter, phase 2 clinical trial of ipilimumab plus nivolumab was conducted across multiple rare tumor cohorts. The dedicated, high-grade neuroendocrine neoplasm cohort … hugo boss tasche sale